Effect of iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells
Iguratimod (IGU, also known as T-614), a novel disease modifying antirheumatic drug intended to cure patients with rheumatoid arthritis (RA). The purpose of this study is to evaluate the effect of IGU on the pharmacokinetics of CYP2C9 probe drug diclofenac and its metabolite 4′-hydroxy diclofenac in...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Universidade de São Paulo
|
Series: | Brazilian Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502019000100523&lng=en&tlng=en |